- It's possible Allergan (AGN +0.8%) could defeat Valeant's (VRX +1.8%) bid for the company, but Allergan (in which Paulson has a 6M share stake at last report) can't continue to stand alone, says John Paulson at the Delivering Alpha conference.
- There's no company which has done more to enhance shareholder value than Valeant, says Paulson, noting the stock is up about 800% since embarking on its "accretive acquirer" strategy. He plans to discuss Bill Ackman's effort to toss the Allergan board in a conference call with the Pershing Square chief tomorrow.
- Previously: Paulson jumps in Allergan